Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

Share Price is delayed by 15 minutes
Get Live Data
14.00    0.00 (0.00%)
Bid:
13.50
Ask:
14.50
Spread: 1.00 (7.407%)
Market Cap: £17.67m
INSG Live PriceLast checked at - London Stock Exchange

Intraday Insig Ai Plc Share Chart

Equity fundraise

7 Oct 2025 07:00

RNS Number : 2833C
Insig AI Plc
07 October 2025
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) NO. 596/2014. It forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this information is considered to be in the public domain.

 

Insig AI plc

("Insig AI", the "Company" or the "Group")

 

 

Equity fundraise

 

Insig AI plc (AIM:INSG), a provider of AI-led analytics and machine learning solutions is pleased to announce that following receipt of an unsolicited offer of equity investment, it has raised gross proceeds of approximately £500,000 at 30p per ordinary share of 1 pence each ("Ordinary Share") (the "Placing"). The placing price represents a discount of 7.41% to the closing share price on 6 October 2025 of 32.4p. The Placing proceeds will be used for general working capital purposes including bolstering Insig's sales activities and the continuing evaluation of the Company's strategic options including the potential establishment of a fund dedicated to investments in digital assets and related enterprises. The Placing will be satisfied by the issue of 1,666,666 Ordinary Shares (the "Placing Shares"). CMC Markets UK Plc ("CMC"), trading as CapX, acted as the Company's sole placing agent in respect of the Placing.

 

 

Insig AI is also pleased to report that unaudited revenues for the six months to 30 September 2025 were circa £421k, more than 155% ahead of the equivalent period last year (£165k). This represents a further acceleration from the three months to 30 June 2025, where comparable sales growth was 143%.

 

Insig AI is also pleased to announce that CMC has been appointed as the Company's joint corporate broker.

 

Admission and Total Voting Rights

 

Application will be made to the London Stock Exchange for admission of the Placing Shares to trading on AIM ("Admission"). Admission is expected to become effective, and dealings in the Subscription Shares are anticipated to commence on or around 13 October 2025.

 

Following Admission, the issued share capital and total voting rights of the Company will be 123,349,309. Shareholders may use this figure as the denominator to determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Richard Bernstein, Chief Executive commented: "We're pleased to have attracted this offer of equity capital. It enables us to allocate further resource towards the evaluation of strategic options including the potential establishment of a fund dedicated to digital assets and related enterprises as well as being able to invest for additional sales growth from our current and planned new product offerings. Furthermore, with these various initiatives and evaluations taking shape, now is the time to have CMC Markets, with its impressive reach and market positioning, as our joint broker."

 

 

For further information, please visit www.insig-ai.com or contact:

 

Insig AI plc

Richard Bernstein, CEO

richard.bernstein@insg.ai

 

Zeus (Nominated Adviser & Joint Broker)

David Foreman / James Hornigold

+44 (0) 203 829 5000

 

CMC Markets (Joint Broker)

Douglas Crippen + 44 (0) 203 003 8632

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAFEKEEASFAA
Date   Source Headline
8th Nov 20227:00 amRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSNew Contract Win
3rd Nov 20227:00 amRNSTrading update
26th Oct 20227:00 amRNSConvertible Loan Facility drawdown
17th Oct 20227:00 amRNSPartnership agreement with BRAIN
12th Oct 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
30th Sep 202212:13 pmRNSResult of Annual General Meeting & General Meeting
30th Sep 20227:00 amRNSContract win
26th Sep 20227:00 amRNSConvertible Loan Facility drawdown
20th Sep 20227:00 amRNSChange of Registered Office
12th Sep 20227:00 amRNSConvertible Loan Facility Agreement
9th Sep 20227:00 amRNSFinal Results, Posting of Report and Notice of GM
8th Sep 20227:00 amRNSNotice of AGM
30th Aug 20227:00 amRNSConvertible Loan Facility Agreement and Drawdown
2nd Aug 20227:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSDirector/PDMR Shareholding
26th Jul 20227:00 amRNSConvertible Loan Facility Agreement drawdown
19th Jul 20227:00 amRNSDirectors' Disclosure
6th Jul 20227:00 amRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 202210:30 amRNSConvertible loan agreement and drawdown
31st May 20227:00 amRNSData partnership and research agreement
5th May 20227:00 amRNSData share partnership agreement with Snowflake
4th May 20227:00 amRNSConvertible Loan Facility Agreement and drawdown
28th Apr 20227:00 amRNSUpdate on agreement with CarVal Investors, L.P
26th Apr 20227:00 amRNSDirector/PDMR Shareholding
25th Apr 20227:00 amRNSContract win, trading update and Board changes
11th Apr 20227:00 amRNSDirectorate Change
24th Mar 20227:00 amRNSDirector/PDMR Shareholding
22nd Mar 20227:00 amRNSDirector/PDMR Shareholding
21st Mar 20227:00 amRNSTrading and operations update
25th Feb 20227:00 amRNSFurther agreement with CarVal Investors, L.P.
7th Feb 20227:00 amRNSInsig AI selected for PwC Scale FinTech programme
14th Jan 20227:00 amRNSDirector/PDMR Shareholding
6th Jan 20221:41 pmRNSDirector/PDMR Shareholding
30th Dec 20217:00 amRNSDirectorate change
23rd Dec 202112:55 pmRNSDirector/PDMR Shareholding
23rd Dec 20218:42 amRNSDirector/PDMR Shareholding
22nd Dec 20217:00 amRNSInterim Results
13th Dec 20217:00 amRNSContract win
10th Dec 20217:00 amRNSColm McVeigh appointment to the Board
19th Nov 202111:36 amRNSDirector/PDMR Shareholding
19th Nov 20217:00 amRNSDirector/PDMR Shareholding
18th Nov 20217:00 amRNSAcquisition of FDB Systems Limited
15th Nov 20217:00 amRNSProof of concept signed with asset manager
10th Nov 20217:00 amRNSESG scoring solution delivered to CarVal Investors
10th Nov 20217:00 amRNSColm McVeigh appointed as Chief Commercial Officer
4th Nov 20217:00 amRNSInvestor Presentation
1st Nov 20217:00 amRNSInsig AI Becomes a Sponsor of the UK's APPG on ESG
4th Oct 20217:00 amRNSRelease of Insig Portfolio 2.0

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.